Focus Partners Advisor Solutions LLC Purchases 7,307 Shares of Johnson & Johnson $JNJ

Key Points

• Focus Partners Advisor Solutions LLC increased its stake in Johnson & Johnson by 22%, owning 40,511 shares valued at $6.72 million after acquiring an additional 7,307 shares.
• Johnson & Johnson reported Q2 earnings of $2.77 EPS, exceeding expectations, with revenues of $23.74 billion, reflecting a 5.8% year-over-year increase.
• The company announced a quarterly dividend of $1.30 per share, resulting in a 2.9% dividend yield and a payout ratio of 55.61%.

Focus Partners Advisor Solutions LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 22.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 40,511 shares of the company's stock after purchasing an additional 7,307 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in Johnson & Johnson were worth $6,718,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in JNJ. Lantz Financial LLC boosted its stake in Johnson & Johnson by 3.3% in the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after purchasing an additional 377 shares during the period. Apexium Financial LP increased its position in Johnson & Johnson by 10.7% during the first quarter. Apexium Financial LP now owns 23,989 shares of the company's stock worth $3,978,000 after acquiring an additional 2,310 shares during the period. Joel Isaacson & Co. LLC boosted its stake in shares of Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after buying an additional 2,526 shares during the period. State of Wyoming grew its holdings in shares of Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after purchasing an additional 10,279 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. raised its position in Johnson & Johnson by 7.0% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock valued at $12,164,000 after purchasing an additional 4,816 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.2%

Shares of JNJ stock traded down $0.35 on Wednesday, hitting $177.71. 6,832,001 shares of the company's stock traded hands, compared to its average volume of 7,666,583. The stock has a market capitalization of $427.98 billion, a price-to-earnings ratio of 17.72, a P/E/G ratio of 2.26 and a beta of 0.40. The company's fifty day simple moving average is $167.02 and its 200 day simple moving average is $160.33. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company's revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research reports. Morgan Stanley increased their price target on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. UBS Group boosted their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Wall Street Zen lowered Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Finally, Citigroup upped their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday, August 21st. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.